Caring Brands Inc. (Nasdaq: CABR) completed the initial closing of a $9 million private placement on September 1, 2026, issuing $4.6 million in convertible preferred shares to accredited investors under a Purchase Agreement, according to the company's September 2, 2026 Form 8-K and accompanying GlobeNewswire release.

The deal is not yet done. The company's September 2, 2026 GlobeNewswire release states that $4,400,000 of subscription documents have been executed and the company is waiting for those funds to clear. Upon release, Caring Brands expects to issue an additional 4,400 shares of Series B Preferred Stock, Series A Warrants to purchase up to 4,400,000 shares of common stock, and Series B Warrants to purchase up to 4,400,000 shares of common stock. The company expects that second closing to occur on or before September 4, 2026, subject to the satisfaction or waiver of applicable closing conditions.

CEO Dr. Glynn Wilson framed the raise in operational terms: "We are now ready to begin funding our full domestic and international marketing campaigns and create the Company's proprietary salesforce, moves that should enable us to substantially increase revenues at a quicker pace."

The context behind that ambition is stark. Caring Brands reported $4,000 in revenue and a $6.3 million net loss for fiscal 2025, per StockTitan's reporting on the company's financials. The company had 8,941,506 shares outstanding as of its May 2026 filing.

This is not CABR's first trip to the private placement window this year. On July 10, 2026, the company entered into a Securities Purchase Agreement with one accredited investor for 443.2133 shares of Series A Convertible Preferred Stock, priced at $950 per share against a stated value of $1,000 per share — a 5% original issue discount — generating $400,000 in gross proceeds, per StockTitan's SEC filings coverage. The Series A Preferred Stock carries a conversion price of $0.40 per share.

Compliance risk remains on the table. Caring Brands has received a Nasdaq notice for failing to meet the exchange's $2.5 million stockholders' equity requirement. The stock continues to trade under the symbol CABR, but the company has disclosed there can be no assurance it will regain compliance; failure to do so could result in its common stock becoming subject to delisting.

On the trading session of September 2, 2026, CABR shares ranged between $1.20 and $1.38, against a previous closing price of $1.22, with a daily trading volume of $161.04K shares and a market capitalization of $12.27 million, per the Kraken quote page.

The company's product portfolio spans several therapeutic and consumer categories: the Hair Enzyme Booster (JW-700) for hair growth; Photocil for psoriasis and vitiligo; CB-101 for atopic dermatitis; NoStingz for jellyfish, sea lice, and UVA/UVB protection; GoldN for Ebola diagnostics; and women's sexual wellness products.

The next material event to watch is the second closing, targeted on or before September 4, 2026 — at which point the full $9 million raise will either be complete or the company will need to account for any shortfall.